Document:

<PAGE>
                                                                   EXHIBIT 10.28

                                LICENSE AGREEMENT

This agreement is made the 6th day of December, 2006 (the "Effective Date"),
between:

MCMASTER UNIVERSITY, an institution, with a principal place of business at 1280
Main St. W. MIP 100, Hamilton, Ontario L8S 4L8, Canada, Tel: 905-525-9140 ext
22176, Fax: 905-546-1372 (herein called "McMaster" or "University")

      - and -

MOLECULAR INSIGHT PHARMACEUTICALS, INC., a corporation with a principal place of
business at 160 Second Street Cambridge, MA 02142, Tel: 617.492.5554, Fax:
617.492.5664 (herein called the "Licensee"); each a Party to this Agreement
(herein, collectively called the "Parties").

WHEREAS, McMaster is the owner of the Technology (as defined herein below) and
has the exclusive world-wide right to license and sublicense the Technology; and

WHEREAS, Licensee wishes to license the Technology for the purpose of developing
and commercializing products using the Technology within the permitted
Field-of-Use (as defined herein below);

NOW, THEREFORE, in consideration of the mutual covenants and agreements
hereinafter contained, the parties agree as follows:

                                   DEFINITIONS

"CONFIDENTIAL INFORMATION" means any part of the information which is designated
by a Party as confidential, whether orally or in writing but excluding any part
of the information:
      (i)   possessed by a first Party prior to receipt from the second Party,
            other than through prior disclosure, as evidenced by the first
            Party's written records;
      (ii)  published or available to the general public otherwise than through
            a breach of this Agreement;
      (iii) obtained by a Party from a third party with a valid right to
            disclose it, provided that said third party is not under a
            confidentiality obligation to the other Party to this Agreement; or
      (iv)  independently developed by employees, agents or consultants of a
            Party who had no knowledge of or access to the information as
            evidenced by the Party's written records.

"FIELD-OF-USE" means the discovery, development, preparation and use of
radiopharmaceuticals in diagnostic and therapeutic applications.

"LICENSED PROCESS" means any process or procedure that, but for the license
granted herein, would infringe either Technical Information Rights or one or
more claims in the Patent Rights.

"LICENSED PRODUCTS" means any product designed and developed by Licensee in the
Field-of-Use that (a) if made, used, offered for sale, sold, imported, leased or
otherwise disposed of in the United States or any other country would, but for
the license granted herein, infringe the Technical Information Rights or one or
more claims of the Patent Rights, (b) is made by using Licensed Processes, or
(c) when used, practices Licensed Processes.

"NET SALES" means, for any given fiscal year, the total of the gross amounts
billed by Licensee for Licensed Products made, used, leased, transferred, sold
or otherwise disposed of by Licensee, less deductions for (a) cash, trade or
quantity discounts included on the invoice and actually allowed and (b) sales or
use taxes imposed upon particular sales; import/export duties; and
transportation charges, to the extent actually paid. No deductions shall be made
for commissions paid to individuals, whether employed by Licensee or engaged as
independent contractors. The term "Net Sales" shall also include the amount or
fair market

                                       1
<PAGE>

value of all other consideration received by Licensee in respect of a Licensed
Product, including payment in kind, exchange or other transfer of value.

"PATENT RIGHTS" means all rights of McMaster arising under United States and
foreign patents and patent applications related to the Technology, whether
existing on the Effective Date or arising thereafter, and any divisionals,
continuations, continuations-in-part, continued prosecution, reissue or
reexamination applications claiming priority thereto to the extent the claims
are directed to subject matter disclosed in such applications, and any patents
issuing thereon or reissues, reexaminations or extensions thereof. The Patent
Rights are listed at Schedule A.

"PHASE II CLINICAL TRIAL" means a clinical human trial with a Licensed Product
in patients with the targeted medical condition, to assess short-term safety and
diagnostic or therapeutic dose-range finding (minimum and maximum doses) and
determine short-term side effects and risks associated with an investigational
product.

"PHASE III CLINICAL TRIAL" means a pivotal clinical human trial with a Licensed
Product in patients with the targeted medical condition, to demonstrate short
and long term safety and efficacy and assess overall diagnostic or therapeutic
value as well as determine the benefit/risk relationship of an investigational
product, where the trial is of a kind acceptable to the U.S. Food and Drug
Administration or an equivalent foreign regulatory authority elsewhere, as a
submission for approval of a commercial drug product.

"TECHNICAL INFORMATION RIGHTS" means all rights of McMaster in and to all
inventions, trade secrets, copyrights, research data, methods, processes,
know-how and other technical data related to the Technology, whether patentable
or not, whether owned by or licensed to McMaster, and whether existing as of the
Effective Date or arising thereafter if funded by the Licensee under a research
contract.

"TECHNOLOGY" means all technical information and know-how related to or
associated with invention(s) as described in the Patent Rights, and any
modifications, enhancements or improvements thereto.

                                     LICENSE

      1.    Grant. Subject to the terms and conditions of this Agreement,
            McMaster hereby grants to Licensee a world-wide, exclusive license
            under the Patent Rights and to the Technical Information Rights to
            make, have made, use, offer to sell, sell, import, lease or
            otherwise dispose of Licensed Products within the Field-of-Use and
            to practice the Licensed Process in connection with the design,
            development, manufacture and sale of the Licensed Products during
            the term of this Agreement.

      2.    Reserved Rights. Subject to the grant of the exclusive license set
            forth above, Licensee acknowledges that McMaster retains any rights
            not expressly granted to Licensee in Section 1 above, including
            without limitation the right to use the Patent Rights and Technical
            Information Rights for academic research, scholarly publication,
            education, or other non-commercial purposes. McMaster will be free
            to publish the data and results of the Research Project in
            appropriate scientific journals after providing a copy of the
            manuscript to the Licensee and receiving written approval from the
            Licensee within sixty (60) days of manuscript submission to the
            Licensee to prevent the premature public disclosure of
            commercializeable intellectual property or disclosure of Licensee's
            confidential information. If Licensee does not object in writing to
            such publication or presentation within sixty (60) days of receipt
            thereof, it shall be deemed to have agreed to the disclosure and
            McMaster shall be free to proceed. In publishing research results,
            McMaster will undertake all reasonable measures to protect the
            commercial potential of Technology to ensure that the patent
            interests of the Licensee or McMaster are not adversely affected or
            jeopardized. If requested in writing by the Licensee, McMaster will
            defer publication for a maximum period of six (6) months for the
            purposes of obtaining appropriate intellectual property protection.
            Licensee shall not, at

                                       2
<PAGE>

EXHIBIT 10.26  McMaster License

      any time, do or suffer to be done any act or thing which may in any way
      adversely affect any rights of McMaster in and to the Patent Rights or
      Technical Information Rights or any registrations thereof or which,
      directly or indirectly, may reduce the value of the Patent Rights or
      Technical Information Rights.

      3.    Sublicensing. Licensee may sublicense the rights granted pursuant to
            this Agreement provided that: (i) Licensee obtains McMaster's prior
            written consent, which consent shall not be unreasonably withheld;
            (ii) McMaster shall receive such revenue or royalty payment as is
            provided in Section 4 below; and (iii) any such sublicense shall not
            derogate in any way the obligations of Licensee hereunder. The
            Parties acknowledge that Licensee may choose to distribute Licensed
            Products through third party-contracted distributors which shall not
            be deemed to be an assignment or sublicense subject to this
            provision provided such distributors are not using the Patent Rights
            or Technical Information Rights to manufacture or modify the
            Licensed Products. A sublicense under this Agreement as well as the
            rights that accrue to a sublicense(s) thereunder, shall survive the
            termination of this Agreement pursuant to Section 17.

      4.    Payments. In consideration of the license herein granted, Licensee
            shall pay or cause to be paid to McMaster:

            (a)   an initial licensing fee of ** payable within 90
                  days following execution of this Agreement. The initial
                  license fee is non-refundable and is required to reimburse
                  McMaster for its costs of developing, protecting and licensing
                  the Technology;

            (b)   royalty of Net Sales on Licensed Products sold by Licensee or
                  sublicensee in any country in which Patent Rights exist,
                  according to the following schedule: ** for diagnostic
                  applications of the Licensed Products and ** for therapeutic
                  applications of the Licensed Products. In the event that
                  Licensee's total royalty burden on any Licensed Product sold
                  exceeds ** (depending on whether it involves a diagnostic or
                  therapeutic product) wherein ** or ** is the royalty stack cap
                  expressed as a percentage of Net Sales receipts), then,
                  because of the need for licensing additional components, the
                  royalty payable hereunder shall be reduced by an amount
                  proportionate to the amount by which the total royalty exceeds
                  the royalty stack cap. However, in no event shall the adjusted
                  reduced royalty rate be less than ** of the applicable ** or
                  ** royalty due hereunder.

      Specifically:

                         R2 = R1 x (royalty stack cap/T)
      where:
            R1 is the royalty due hereunder
            R2 is the adjusted reduced royalty rate due hereunder
            T is the total royalty due to all licensors, and
            The royalty stack cap is either ** for all diagnostic Licensed
                Products, or ** for all therapeutic Licensed Products.
            Forexample, if two additional licenses are needed from two
                additional third parties in order to obtain freedom to operate
                to make, use and sell a therapeutic Licensed Product, and these
                two other royalty rates are 2% and 4.0% (total of 6.0% third
                party royalties), the value of T is ** and the recalculated
                royalty rate (R2), is ** x ** or **. Since R2 is never
                less than ** of R1, the adjusted royalty rate due under this
                Agreement is **.

      (c) Minimum annual royalties shall be paid by Licensee to McMaster; such
      minimum annual royalty payments shall be non-refundable, except that for
      any year where the minimum royalty stated hereunder exceeds the earned
      royalties described in Section 4(b) above, Licensee shall be able to
      credit such excess

* confidential treatment requested *

                                       3
<PAGE>

      payment against any royalties due in the subsequent year. Minimum annual
      royalties shall be paid according to the following schedule, based on the
      Effective Date of this Agreement:

              i.    1st anniversary -- USD **
             ii.    2nd anniversary -- USD **
            iii.    3rd anniversary -- USD **
             iv.    4th anniversary -- USD **
              v.    5th and subsequent anniversaries -- USD **

      (d) Licensee's obligation to pay a royalty under Section 4b shall
      terminate on a country-by-country basis upon expiry of Patent Rights in
      such country.

      (e) Where Licensed Products are not sold separately, but are sold in
      combination with or as parts or components of other products, the Net
      Sales of the Licensed Products shall be calculated for the purpose of
      computing payments due under this Agreement by applying to the total net
      sales price of the combined or composite products a fractional multiplier
      having as its numerator the manufacturing cost of the Licensed Product,
      and as its the denominator the total manufacturing cost of the combined or
      composite products (determined in accordance with the Licensee's customary
      accounting procedures) including the Licensed Product;

      (f) Payments made pursuant to Section 4 shall be paid by wire transfer, or
      other means mutually agreed upon by the Parties, within 90 days following
      the close of the calendar quarter during which the Net Sales underlying
      such royalties have actually been received by Licensee. Each payment shall
      be accompanied by a statement of account of the payments due hereunder and
      the number of Licensed Products sold, licensed or otherwise provided, the
      dates thereof and the terms of sale.

      (g) In the event that the Licensee fails to make any payment when such
      payment is due hereunder, the amount of such payment shall bear interest
      at the rate equal to the minimum lending rate to prime commercial
      borrowers established by McMaster's banker plus one percent (1%)
      calculated from the date due until the date paid provided that the payment
      of such interest shall not be deemed an alternate for the sums owing on
      the due dates which payments shall be deemed to be in default and remain
      subject to the termination provisions herein.

      (h) In addition to the royalty payments set forth in Section 4b and 4c,
      Licensee shall make the milestone payments set forth below. Milestone
      payments shall apply only to the first time for each new Licensed Product
      in any indication. For avoidance of doubt, if Licensee should choose to
      enter into more than one clinical trial with a Licensed Product (for
      example, multiple IND applications) or a trial with more than one Licensed
      Product, then the milestone payments for subsequent trials or additional
      Licensed Product shall only apply to the first indication or to one (1)
      Licensed Product in the event that two (2) or more Licensed Products are
      used. Licensee shall make the following payments:

            i.    Upon initiation of a Phase I Clinical Trial, the sum of
                  **
            ii.   Upon initiation of a Phase II Clinical Trial, the sum of **
            iii.  Upon successful completion of a Phase III Clinical Trial, the
                  sum of **
            iv.   Within ninety (90) days of first commercial sale of a Licensed
                  Product, the sum of **
            v.    The milestone payments paid to Licensor as provided in Section
                  4(h)(i-iv) above, shall be creditable against royalties due
                  under Section 4c.

                                       4

* confidential treatment requested *

<PAGE>

      5.    Performance Guarantees. The Licensee will use commercially
            reasonable efforts to develop, market, and sell the Licensed
            Products. In the event that McMaster is of the view that the
            Licensee is not using its best efforts, it may call for an
            evaluation to be conducted by a mutually agreed upon evaluator. If
            the evaluator determines that Licensee is not using commercially
            reasonable efforts, or if the Licensee does not sell a first
            Licensed Product on or before seven (7) years from the Effective
            Date of this Agreement, McMaster may, at its option, terminate the
            Agreement or change the rights granted pursuant to the Agreement
            from exclusive to non-exclusive, or restrict the Field-of-Use.

      6.    Information Rights. Licensee shall prepare and maintain complete and
            accurate books and records covering all transactions arising out of
            or relating to this Agreement or the carrying on of its business in
            respect of the Licensed Products. Provided these records disclose
            information about the Net Sales of Licensed Products, Licensee shall
            provide to McMaster financial information including, but not limited
            to the following:

            (a)   Quarterly financial statements: Within 30 days after the last
                  day of each quarter, financial statements, including a balance
                  sheet and a statement of income related to the terms and
                  volume of Net Sales of the Licensed Products as of the last
                  date of each quarter;

            (b)   Annual financial statements: Within 120 days after the end of
                  each fiscal year of the Licensee, financial statements
                  detailing the terms and volume of Net Sales of the Licensed
                  Products prepared in accordance with generally accepted
                  accounting principles (GAAP), reviewed and/or audited by a
                  reputable accounting firm;

            (c)   All such books of account, records and documents related to
                  the statements provided under Sections 6(a) and 6(b) shall be
                  kept available by Licensee for at least two (2) years after
                  termination of this Agreement; and

            (d)   McMaster and its duly authorised representatives shall have
                  the right, upon giving Licensee ten (10) days notice, at its
                  own expense and during regular business hours, for the
                  duration of the Agreement and for two (2) years thereafter, to
                  inspect and audit Licensee's records relating to the
                  Technology licensed under this Agreement.

      7.    Patents. McMaster owns all of the patents and patent applications
            identified as the Patent Rights, including all foreign counterparts
            and continuation applications and reissued patents. McMaster shall
            own all patent applications claiming improvements to the technology
            disclosed in the Patent Rights, except those applications disclosing
            improvements developed solely by the Licensee. Licensee will oversee
            the prosecution and maintenance of all Patent Rights, including all
            patents for McMaster improvements. The Licensee will bear all costs
            for preparation, filing, prosecution and maintenance of the Patent
            Rights, and in return will have the right to designate which
            improvements should be patented and shall become a licensee of all
            resulting McMaster improvement patents on the same terms as provided
            in this Agreement without any further action required on the part of
            either party. Should Licensee elect not to pursue patent protection
            on one or more of the applications or patents in the Patent Rights,
            or on a McMaster improvement (a "Nonelected Patent"), then McMaster
            may assume all rights and responsibility for the Nonelected Patent,
            and the Nonelected Patent shall be excluded from the Patent Rights
            licensed hereunder. The Licensee will ensure proper patent marking
            for all Licensed Products subject to patent protection as well as
            provide copies of all correspondence to McMaster that are related to
            the prosecution and maintenance of the Patent Rights, including all
            patents and applications for McMaster improvements.

      8.    Further Assurances. At the request of the Licensee, McMaster will
            use its best efforts to timely provide documents or information
            required by Licensee to file, prosecute, or maintain all patent
            applications giving rise to Patent Rights. Licensee shall execute
            any documents, reasonably requested by McMaster

                                       5
<PAGE>

            to confirm McMaster's and/or other inventors' rights in and to the
            Technology and Patent Rights, and the respective rights of the
            Licensee in the Technology and Patent Rights pursuant to this
            Agreement. Licensee shall cooperate, at its expense, in connection
            with the filing and prosecution of applications to register any
            rights or interest in or to the Technology and Patent Rights.

      9.    Infringement.

            (a)   Notice Regarding Infringement. Each party shall inform the
                  other promptly in writing of any alleged infringement of the
                  Patent Rights or the Technical Information Rights by a third
                  party and of any available evidence thereof.

            (b)   Right of Licensee to Prosecute Suit. Licensee shall have the
                  right, but shall not be obligated, to prosecute at its own
                  expense all infringements of the Patent Rights and Technical
                  Information Rights. In furtherance of such right, McMaster
                  hereby agrees that Licensee may include McMaster as a party
                  plaintiff in any such suit, without expense to McMaster;
                  provided, however, that such right to bring such an
                  infringement action shall remain in effect only during such
                  time as this Agreement remains in effect. No settlement,
                  consent judgement or other voluntary final disposition of the
                  suit may be entered into as to the Patent Rights without the
                  consent of McMaster, which consent shall not unreasonably be
                  withheld. Licensee shall indemnify McMaster against any order
                  for costs that may be issued against McMaster in such
                  proceedings.

            (c)   Right of McMaster to Prosecute Suit. If within six (6) months
                  after having been notified of an alleged infringement,
                  Licensee shall have been unsuccessful in persuading the
                  alleged infringer to desist and shall not have brought an
                  infringement action, or if Licensee shall notify McMaster at
                  any time prior thereto of its intention not to bring suit
                  against any alleged infringer, then McMaster shall have the
                  right, but shall not be obligated, to prosecute at its own
                  expense any infringement of the Patent Rights. No settlement,
                  consent judgement or other voluntary final disposition of the
                  suit may be entered into that would result in invalidity of
                  any Patent Right licensed to Licensee hereunder without the
                  consent of Licensee, which consent shall not unreasonably be
                  withheld. In the event that Licensee withholds its consent,
                  Licensee shall indemnify McMaster against any costs associated
                  with the defence against claims of patent invalidity.

      10.   McMaster Representations and Warranties. McMaster warrants that it
            has the power and authority to enter into this Agreement and has no
            knowledge as to any third party claims regarding proprietary rights
            in the Technology, Patent Rights or Technical Information Rights
            which would interfere with the rights granted under this Agreement.
            McMaster warrants that it owns all right, title and interest in the
            Technology.

      11.   Licensee Representations and Warranties. Licensee hereby represents
            and warrants as of the date hereof that:

            (a) Licensee is a corporation duly organised and validly existing
            under the laws of the Commonwealth of Massachusetts and has all
            requisite corporate power and authority to execute, deliver and
            perform its obligations under this Agreement and to consummate the
            transactions contemplated hereby;

            (b) Licensee has the full right and authority to enter into this
            Agreement, including without limitation the right to grant the
            licenses granted by it hereunder;

            (c) Licensee acknowledges that it does not own the Patent Rights
            listed at Schedule A; and

      12.   Disclaimer Of Warranties. EXCEPT FOR THE REPRESENTATIONS AND
            WARRANTIES SET

                                       6
<PAGE>

            FORTH IN SECTIONS 10 AND 11 HEREOF, NOTHING CONTAINED IN THIS
            AGREEMENT SHALL BE CONSTRUED AS: (A) A WARRANTY OR REPRESENTATION OF
            EITHER PARTY AS TO THE VALIDITY, ENFORCEABILITY OR SCOPE OF ANY
            INTELLECTUAL PROPERTY RIGHT LICENSED HEREUNDER; (B) A WARRANTY OR
            REPRESENTATION THAT THE EXERCISE OF ANY OF THE RIGHTS GRANTED
            HEREUNDER WILL BE FREE FROM INFRINGEMENT OF THE INTELLECTUAL
            PROPERTY RIGHTS OF THIRD PARTIES; (C) AN AGREEMENT TO BRING OR
            PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENT;
            OR (D) EXCEPT AS EXPRESSLY PROVIDED HEREIN, REQUIRING EITHER PARTY
            TO FILE AN APPLICATION FOR PATENT, SECURE ANY PATENT OR MAINTAIN ANY
            PATENT IN FORCE. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER PARTY
            MAKES ANY EXPRESS WARRANTIES AND EACH PARTY EXPRESSLY DISCLAIMS ANY
            IMPLIED WARRANTIES INCLUDING, WITHOUT LIMITATION, THE IMPLIED
            WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A
            PARTICULAR PURPOSE. MCMASTER MAKES NO WARRANTY AS TO THE SUFFICIENCY
            OR SUITABILITY FOR LICENSEE'S USE OF THE PATENT RIGHTS OR THE
            TECHNICAL INFORMATION RIGHTS, AND NEITHER PARTY ASSUMES ANY
            RESPONSIBILITY OR LIABILITY FOR LOSS OR DAMAGES, WHETHER DIRECT OR
            INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR SPECIAL, WHICH MAY
            ARISE OUT OF THE OTHER PARTY'S USE OF SUCH INFORMATION OR
            INTELLECTUAL PROPERTY TO DESIGN, MANUFACTURE OR FABRICATE PRODUCTS,
            OR WHICH MAY ARISE OUT OF SUCH OTHER PARTY'S SALE OF SUCH PRODUCTS
            DESIGNED, MANUFACTURED OR FABRICATED USING OR INCORPORATING SUCH
            INFORMATION OR INTELLECTUAL PROPERTY, AND EACH PARTY SHALL BE SOLELY
            RESPONSIBLE FOR THE QUALITY, PERFORMANCE, RELIABILITY AND SAFETY OF
            PRODUCTS MANUFACTURED BY OR FOR SUCH PARTY.

      13.   Indemnification. Licensee shall at all times during the term of this
            Agreement and thereafter, defend, indemnify and hold harmless
            McMaster, its directors, officers, employees, agents and affiliates,
            from and against any and all liability, damage, loss, cost or
            expense of any kind whatsoever (including reasonable attorneys'
            fees) incurred by or imposed upon McMaster in connection with any
            and all claims, suits, actions, demands, proceedings, causes of
            action or judgements (including, without limitation, product
            liability claims) resulting from or arising out of the production,
            manufacture, use, marketing or sale of Licensed Products or Licensed
            Processes or Licensee's breach of any of its obligations hereunder.
            McMaster shall promptly notify Licensee of any such claim(s) of
            which McMaster is aware. Licensee, at Licensee's sole expense, shall
            maintain control and direction of the defence of such claims brought
            against McMaster, provided, however, that McMaster shall have the
            right to participate in such defence at McMaster's expense. McMaster
            agrees to provide Licensee with any and all reasonable assistance
            which Licensee may request in connection with its defence of such
            claims.

      14.   Insurance. Prior to any use of a Licensed Product in humans, the
            Licensee will be required to obtain insurance in amounts and on
            terms that are customary for companies in the biotechnology industry
            who are creating diagnostic and therapeutic compounds for
            administration to humans. Insurance shall be maintained as long as
            Licensed Products are administered to human subjects. If any
            sublicenses are granted, sublicensees will also be required to
            obtain similar insurance.

      15.   Confidentiality. Confidential Information shall be developed,
            received and used by the Parties solely in furtherance of the
            purposes set forth in this Agreement subject to the terms and
            conditions set forth in this Section 15.

            (a)   Subject to the limitation set for the in paragraph (b) below,
                  the Parties shall keep and use all of the Confidential
                  Information in confidence and will not, without the prior
                  written consent of the other Party, disclose any Confidential
                  Information to any person or entity, except those of the
                  Parties' officers, employees and professional advisors who
                  require said Confidential Information in

                                        7

<PAGE>

                  performing their obligations under this Agreement. The Parties
                  covenant and agree to initiate and maintain appropriate
                  internal programs limiting the internal distribution of the
                  Confidential Information to only those officers, employees,
                  researchers and professional advisors who require said
                  Confidential Information to perform their obligations under
                  this Agreement.
            (b)   Notwithstanding the restrictions detailed in Section 15(a),
                  Licensee shall have the right to disclose any or all
                  Confidential Information, without prior notice or consent of
                  McMaster, as may be required by any regulatory authority,
                  including, e.g., but not limited to, the United States
                  Securities and Exchange Commission, or the U.S. Food and Drug
                  Administration. Where available, Licensee shall request
                  confidential treatment of certain Confidential Information. (
            c)    If a Party is required by judicial or administrative process
                  to disclose any or all of the Confidential Information, the
                  Party shall promptly notify the other Party and allow if
                  possible the other Party reasonable time to oppose such
                  process before disclosing any Confidential Information.

      16.   Term. Unless sooner terminated pursuant to paragraphs (a) or (b)
            below, the license herein granted shall commence on the Effective
            Date of this Agreement and continue until the last to expire of any
            Patent Rights.

            (a)   Licensee shall have the right to terminate the license herein
                  granted upon at least three (3) months written notice of such
                  termination to McMaster.

            (b)   McMaster shall have the right to terminate the license herein
                  granted for any of the following reasons:

                  (i)   for any breach by Licensee of any of its obligations
                        contained in this Agreement, which breach is not cured
                        within thirty (30) days after written notice thereof by
                        McMaster except that, where it is not possible to cure
                        the breach within the said thirty (30) day period, this
                        Agreement shall not be terminated if the Licensee has
                        commenced to cure the breach within the said thirty (30)
                        day period and proceeds diligently thereafter to cure
                        the breach no later then a further sixty (60) days
                        thereafter;

                  (ii)  Licensee fails to meet any of its payments or
                        performance requirements as provided in Section 4; or

                  (iii) bankruptcy or insolvency of Licensee or the appointment
                        of a receiver or liquidator to take charge of the
                        affairs of Licensee or the making of an assignment for
                        the benefit of Licensee's creditors or the equivalent of
                        any such proceedings or acts (whether known by some
                        other name or term), effective immediately upon written
                        notice to Licensee.

      17.   Termination. The following provisions shall take effect upon the
            termination of this license:

            (a)   such termination shall not release Licensee from its
                  obligations with respect to the any payment accrued pursuant
                  to Section 4 up to the date of termination;

            (b)   Licensee shall forthwith following such termination deliver to
                  McMaster a complete and accurate schedule of Licensee's
                  inventory of completed and uncompleted Licensed Products on
                  hand and all unfilled orders for the purchase of Licensed
                  Products;

            (c)   Licensee may sell its inventory of work in progress and
                  Licensed Products on hand on the date of termination but only
                  pursuant to the terms of this Agreement;

            (d)   Licensee shall forthwith, and no later than thirty (30) days
                  after termination, return free of charge to McMaster all
                  written information and documents of whatever kind; including
                  technical data, manuals, reports and programs only to the
                  extent that it embodies, contains or specifically relates to
                  the

                                       8
<PAGE>

                  Technology; and

            (e)   The following obligations under this Agreement, strictly and
                  only in accordance with their express terms shall survive
                  termination of this agreement: Sections 2; 6(c); 6(d); 10;
                  11(c); 13; 14; and 15.

      18.   No Waiver. The failure of either party to exercise their rights
            herein upon the occurrence of any breach by the other party of its
            obligations shall not in any event constitute a waiver of such
            rights if any such breach by the other party should reoccur.

      19.   Assignment. This Agreement and all its rights and privileges
            hereunder may not be assigned by either party without the prior
            written consent of the other party, which consent shall not be
            unreasonably withheld. This Agreement and everything herein
            contained shall inure to the benefit of and be binding upon each of
            the parties hereto and upon their respective successors and
            permitted assigns.

      20.   Construction; Interpretation. This Agreement shall be construed in
            accordance with the laws of the Province of Ontario. This Agreement
            was written in English, and the English language shall control
            interpretation of this Agreement.

      21.   Dispute Resolution. McMaster and the Licensee shall use their best
            efforts to settle in a fair and reasonable manner any dispute
            arising in connection with this Agreement. If such dispute cannot be
            settled by the parties between themselves, it shall be first
            submitted to mediation by a mediator chosen jointly by the parties.
            In the event that mediation does not bring a resolution of the
            dispute within thirty (30) days, the dispute shall be submitted to
            arbitration before a single arbitrator pursuant to the Arbitration
            Act of Ontario and the schedules thereto (as amended from time to
            time).

      22.   Relationship Between the Parties. The parties are not and shall not
            be considered to be joint venturers, partners or agents of each
            other and neither of them shall have the power to bind or obligate
            the other except as set forth in this Agreement. Not withstanding
            the foregoing, this Agreement shall be a collaboration for the
            purposes of 35 U.S.C. 103(c).

      23.   Notice. All notices, demands or other communications required to be
            made or given pursuant to the terms of this Agreement shall be in
            writing and shall be delivered personally, by courier or by prepaid
            first class post, to the parties at their respective addresses as
            hereinafter set out, or such other addresses as the parties may
            subsequently advise in writing. The following shall be the addresses
            for the delivery of notices to each of the parties:

              McMaster:         McMaster University - Office of Research
                                Contracts and Intellectual Property
                                1280 Main Street West, MIP 100
                                Hamilton, Ontario L8S 4L8
                                Attention: Executive Director

              Licensee:         John McCray
                                Chief Operating Officer
                                Molecular Insight Pharmaceuticals, Inc.
                                160 Second Street
                                Cambridge, MA 02142

                                       9
<PAGE>

IN WITNESS WHEREOF the parties hereto, intending to be bound by the terms and
conditions specified herein, have caused this Agreement to be executed by their
duly authorized representatives.

MCMASTER UNIVERSITY

/s/ Arlene Yee                                  Date: Dec. 8, 2006
------------------------------------------            --------------------------
Name: Arlene Yee
Title: Interim Director

MOLECULAR INSIGHT PHARMACEUTICALS, INC.

/s/ John McCray                                 Date: Dec. 6, 2006
------------------------------------------            --------------------------
Name: John McCray
Title: Chief Operating Officer

                                       10
<PAGE>

SCHEDULE  A

<TABLE>
<CAPTION>
                                      COUNTRY
  REFERENCE         APPLICATION         OR         FIRST NAMED
                     SERIAL NO.       REGION        INVENTOR                  TITLE
---------------------------------------------------------------------------------------------
<S>               <C>                 <C>        <C>                <C>
 346715-0562         60/419739          USA      Valliant et al.    METHODS FOR PURIFYING
 (BSA-01760)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0563         2003301432         AU       Valliant et al.    METHODS FOR PURIFYING
 (BSA-01740)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0564          2502358           CA       Valliant et al.     METHODS FOR PURIFYING
 (BSA-01750)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0565         03809042.9         EP       Valliant et al.    METHODS FOR PURIFYING
 (BSA-01780)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0566        2004-545341         JP       Valliant et al.    METHODS FOR PURIFYING
 (BSA-01730)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0567      PCT/US2003/32721      PCT      Valliant et al.    METHODS FOR PURIFYING
 (BSA-01725)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
 346715-0568         10/686950          USA      Valliant et al.    METHODS FOR PURIFYING
 (BSA-01701)                                                        RADIOLABELED COMPOUNDS
---------------------------------------------------------------------------------------------
</TABLE>

                                       11<PAGE>

                                                                    Exhibit 10.1

                FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT

          FIRST AMENDMENT (this "Amendment") dated June __, 2006 to the
Registration Rights Agreement (the "Agreement") dated June 10, 2004, by and
between NaviSite, Inc., a Delaware corporation (the "Company"), and Waythere,
Inc., a Delaware corporation formerly known as Surebridge, Inc. ("Waythere").
All capitalized terms used herein but not otherwise defined shall have the
meanings ascribed to such terms in the Agreement. The Agreement shall continue
in full force and effect in accordance with its terms, except to the extent
amended hereby.

          NOW, THEREFORE, the parties hereto, in consideration of the mutual
covenants and agreements hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which hereby are acknowledged,
agree as follows:

          (1) Section 1(e) (Incidental Registration) of the Agreement is hereby
     deleted in its entirety and of no further force or effect.

          (2) Section 1(f) (Limitations of Subsequent Registration Rights) of
     the Agreement is hereby deleted in its entirety and of no further force or
     effect.

          (3) Waythere hereby agrees and covenants that it shall not file, or
     cause or permit to be filed, a Form 144 with the Securities and Exchange
     Commission with respect to the sale or proposed sale of any shares of the
     Company's common stock, $0.01 par value per share (the "Common Stock"),
     during the 25 day trading period beginning on June 2, 2006.

          (4) Waythere hereby agrees that it shall not sell or otherwise
     transfer or dispose (collectively, the "Standstill") of any shares of
     Common Stock owned or controlled by it for up to 25 trading days between
     June 2, 2006 and December 31, 2006. Waythere and the Company hereby agree
     that Friday, June 2, 2006 was the first of such 25 trading days, and that
     Waythere shall continue to honor the Standstill after the date hereof until
     the earlier of (i) receipt of written notice from the Company that the
     Standstill has been suspended; or (ii) the end of the twenty-fifth trading
     day after June 2, 2006. The Company shall use its best efforts to provide
     at least one day's written notice to Waythere in the event an additional
     Standstill is imposed by the Company under this Section 4 after the date
     hereof. For the avoidance of doubt, in the event the Company suspends the
     Standstill prior to the expiration of the twenty-fifth trading day, the
     Company shall be permitted at any time prior to December 31, 2006 to impose
     an additional Standstill for up to the number of days equal to 25 less the
     number of trading days that were subject to and included within a
     Standstill previously imposed by the Company pursuant to this Amendment.
     The Company may impose stop-transfer instructions with respect to the
     shares of Common Stock owned by it during any Standstill.

          (5) The parties hereto hereby agree and acknowledge that the first day
     of the 60 day period referenced in Section 1(b)(iv) occurred on June 2,
     2006 and that the suspension of the effectiveness of any Registration
     Statement and the use of the

<PAGE>

     Prospectus shall continue pursuant to the terms thereof until Waythere
     receives written notice thereof from the Company or until such period
     expires by its terms. In addition, the following words "and/or the sales of
     the Registrable Securities" shall be deleted from Section 1(b)(iv) of the
     Agreement and shall be of no further force or effect.

          (6) The Company, or its counsel, shall provide, within five days after
     receipt of a written request from Waythere, an appropriate legal opinion to
     the Company's transfer agent with respect to Rule 144(K) of the Securities
     Act of 1933, as amended (the "Securities Act"), provided that all
     appropriate documentation that is reasonably requested by the Company or
     its counsel is received on such date. In addition, the Company, or its
     counsel, shall provide, within two business days after receipt of a written
     request from Waythere, an appropriate legal opinion to the Company's
     transfer agent with respect to sales by Waythere pursuant to Rule 144 of
     the Securities Act, provided that all appropriate documentation and
     representation letters that are reasonably requested by the Company or its
     counsel is received on such date. Notwithstanding the foregoing, the
     Company and its counsel shall have no obligations under this Section 6 in
     the event (i) the Company or its counsel reasonably determines that
     Waythere is not compliant with the requirements of Rule 144(K) or Rule 144;
     or (ii) Waythere is then subject to a Standstill.

          (7) The definition of "Initial Registrable Securities" is hereby
     amended and restated in its entirety to mean (a) the "Parent Shares" under
     the Purchase Agreement and (b) any shares of capital stock issued or
     issuable, from time to time, upon any reclassification, share combination,
     share subdivision, stock split, share dividend, merger, consolidation or
     similar transaction or event or otherwise as a distribution on, in exchange
     for, of or with respect to, the shares of Common Stock described in (a), in
     each case held at the relevant time by an Investor. As to any particular
     securities, such securities will cease to be Initial Registrable Securities
     (i) when they have been transferred in a public offering registered under
     the Securities Act, (ii) when they have been transferred in a sale made
     through a broker, dealer or market-maker pursuant to Rule 144 under the
     Securities Act, (iii) when the Investors (including for this purpose the
     stockholders of Waythere) are or would be able to sell all of such
     securities under Rule 144 under the Securities Act during any 90-day period
     without restriction (including without limitation, as to volume by the
     holder thereof), (iv) on January 1, 2007, or (v) when they have been
     transferred other than as permitted by the Purchase Agreement, the Notes
     and this Agreement.

          (8) Section 1(a)(ii) is hereby amended to read in its entirety "The
     Company shall use its reasonable best efforts to cause any such Initial
     Registration Statement described in Section 1(a)(i) to remain effective (or
     if required by applicable law, to cause another Registration Statement with
     respect to the Initial Registrable Securities to become effective) until
     the earlier of (i) such time as all of such securities have been sold by
     Waythere and (ii) December 31, 2006."

                [Remainder of this page intentionally left blank]

                                        2

<PAGE>

          IN WITNESS WHEREOF, each of the parties hereto has executed this
Amendment, or caused this Amendment to be duly executed on its behalf, as of the
date first written.

                                        NAVISITE, INC.

                                        By: /s/ John J. Gavin, Jr.
                                            ------------------------------------
                                        Name: John J. Gavin, Jr.
                                        Title: Chief Financial Officer

                                        WAYTHERE, INC.

                                        By: /s/ Mathew Hills
                                            ------------------------------------
                                        Name: Mathew Hills
                                              ----------------------------------
                                        Title: Director
                                               ---------------------------------

                                        3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]